EYPT Stock Analysis: Eyepoint Pharmaceuticals | NASDAQ

Biotechnology | NASDAQ, USA | Market Cap: 1.199m USD | 12M Return: 47.7% | Charts, Fundamentals & Technical Analysis

Retinal Therapeutics, Sustained Delivery, Macular Treatments, Kinase Inhibitors
Total Rating 26
Safety 38
Buy Signal -1.16
Biotechnology
Industry Rotation: +30.9
Market Cap: 1.20B
Avg Turnover: 18.0M
Risk 3d forecast
Volatility81.5%
VaR 5th Pctl12.9%
VaR vs Median-3.80%
Reward TTM
Sharpe Ratio0.86
Rel. Str. IBD42
Rel. Str. Peer Group35.2
Character TTM
Beta0.844
Beta Downside0.469
Hurst Exponent0.580
Drawdowns 3y
Max DD86.10%
CAGR/Max DD0.18
CAGR/Mean DD0.29
EPS (Earnings per Share) EPS (Earnings per Share) of EYPT over the last years for every Quarter: "2021-06": -0.42, "2021-09": -0.58, "2021-12": -0.59, "2022-03": -0.52, "2022-06": -0.52, "2022-09": -0.49, "2022-12": -1.16, "2023-03": -0.56, "2023-06": -0.61, "2023-09": -0.33, "2023-12": -0.33, "2024-03": -0.55, "2024-06": -0.58, "2024-09": -0.54, "2024-12": -0.64, "2025-03": -0.65, "2025-06": -0.85, "2025-09": -0.85, "2025-12": -0.81, "2026-03": -0.99,
Last SUE: -2.77
Qual. Beats: -1
Revenue Revenue of EYPT over the last years for every Quarter: 2021-06: 9.013, 2021-09: 9.059, 2021-12: 11.544, 2022-03: 9.294, 2022-06: 11.565, 2022-09: 10.012, 2022-12: 10.533, 2023-03: 7.683, 2023-06: 9.105, 2023-09: 15.202, 2023-12: 14.028, 2024-03: 11.684, 2024-06: 9.477, 2024-09: 10.524, 2024-12: 11.588, 2025-03: 24.453, 2025-06: 5.333, 2025-09: 0.966, 2025-12: 0.62, 2026-03: 0.696,
Rev. CAGR: -24.78%
Rev. Trend: -48.1%
Last SUE: 0.06
Qual. Beats: 0

Warnings

Strong Share Dilution
Interest Coverage Ratio Critical
Beneish M-Score Likely Earnings Manipulation
Altman Z'' In Financial Distress Zone
Volatile
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 10.5 years of data

Jan +14.7% 46
Feb -0.5% 2
Mar -0.5% 10
Apr +0.2% 0
May -5.0% 28
Jun -2.5% 25
Jul +8.2% 13
Aug +3.5% 24
Sep +0.9% 2
Oct -11.2% 22
Nov +7.6% 20
Dec -1.8% 5

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: EYPT Eyepoint Pharmaceuticals

EyePoint, Inc. (NASDAQ: EYPT) is a specialty pharmaceutical company focused on developing and commercializing therapeutics for serious retinal diseases. The company leverages its proprietary Durasert E technology, a bioerodible sustained intraocular drug delivery platform, to reduce treatment burden associated with frequent intravitreal injections common in ophthalmology.

Its lead candidate, DURAVYU, combines vorolanib (a tyrosine kinase inhibitor) with Durasert E and is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The pipeline also includes EYP-2301, a preclinical TIE-2 agonist using the same delivery platform. The company, originally founded in 2000 and headquartered in Watertown, Massachusetts, rebranded from EyePoint Pharmaceuticals, Inc. to EyePoint, Inc. in December 2025.

As a small-cap pharmaceutical company, EyePoint operates in the competitive ophthalmology therapeutics space, where sustained-release drug delivery technologies represent a growing area aimed at reducing the dosing frequency typically required with anti-VEGF injections like ranibizumab (Lucentis), aflibercept (Eylea), and faricimab (Vabysmo).

Headlines to Watch Out For
  • DURAVYU Phase 3 wet AMD data readout approaches
  • Eylea HD and Vabysmo pressure DURAVYU market entry
  • Cash burn raises dilution risk through equity offering
Piotroski VR-10 (Strict) 0.0
Net Income: -271.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.94 > 0.02 and ΔFCF/TA -52.48 > 1.0
NWC/Revenue: 2.78k% < 20% (prev 509.1%; Δ 2.28k% < -1%)
CFO/TA -0.93 > 3% & CFO -267.5m > Net Income -271.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.66 > 1.5 & < 3
Outstanding Shares: last quarter (86.0m) vs 12m ago 23.27% < -2%
Gross Margin: 76.51% > 18% (prev 93.29%; Δ -16.79% > 0.5%)
Asset Turnover: 2.34% > 50% (prev 15.46%; Δ -13.12% > 0%)
Interest Coverage Ratio: -7.95k > 6 (EBIT TTM -262.5m / Interest Expense TTM 33.0k)
Altman Z'' -9.86
A: 0.74 (Total Current Assets 249.5m - Total Current Liabilities 37.5m) / Total Assets 288.2m
B: -4.13 (Retained Earnings -1.19b / Total Assets 288.2m)
C: -0.81 (EBIT TTM -262.5m / Avg Total Assets 325.4m)
D: 3.99 (Book Value of Equity 230.5m / Total Liabilities 57.7m)
Altman-Z'' = -9.86 = D
Beneish M -0.05
DSRI: 3.0 (Receivables 1.16m/442k, Revenue 7.62m/56.0m)
GMI: 1.22 (GM 93.29% / 76.51%)
AQI: 3.95 (AQ_t 0.07 / AQ_t-1 0.02)
SGI: 0.14 (Revenue 7.62m / 56.0m)
TATA: -0.01 (NI -271.6m - CFO -267.5m) / TA 288.2m)
Beneish M = -0.05 (Cap -4..+1) = D
What is the price of EYPT shares?

As of July 08, 2026, the stock is trading at USD 14.02 with a total of 2,117,478 shares traded. Over the past week, the price has changed by -0.64%, over one month by +22.45%, over three months by +3.32% and over the past year by +47.73%.

Current recommended Stop Loss: 12.70 (which is 9.4% or 1.3 ATR below the current price).

Is EYPT a buy, sell or hold?

Eyepoint Pharmaceuticals has received a consensus analysts rating of 4.69. Therefore, it is recommended to buy EYPT.

  • StrongBuy: 9
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the EYPT price?
Analysts Target Price 37 163.9%
Eyepoint Pharmaceuticals (EYPT) - Fundamental Data Overview as of 02 July 2026
Market Cap USD = 1.20b (1.20b USD * 1.0 USD.USD)
P/E Forward = 6.1614
P/S = 157.464
P/B = 5.1984
Revenue TTM = 7.62m USD
EBIT TTM = -262.5m USD
EBITDA TTM = -260.1m USD
 Long Term Debt = unknown (none)
 Short Term Debt = unknown (none)
 Debt = 20.2m USD (from shortLongTermDebtTotal, last quarter) (leases 20.2m already included)
Net Debt = -202.3m USD (calculated: Debt 20.2m - CCE 222.5m)
Enterprise Value = 996.6m USD (1.20b + Debt 20.2m - CCE 222.5m)
Interest Coverage Ratio = -7.95k (Ebit TTM -262.5m / Interest Expense TTM 33.0k)
EV/FCF = -3.67x (Enterprise Value 996.6m / FCF TTM -271.5m)
FCF Yield = -27.25% (FCF TTM -271.5m / Enterprise Value 996.6m)
 FCF Margin = -3.57k% (FCF TTM -271.5m / Revenue TTM 7.62m)
 Net Margin = -3.57k% (Net Income TTM -271.6m / Revenue TTM 7.62m)
 Gross Margin = 76.51% ((Revenue TTM 7.62m - Cost of Revenue TTM 1.79m) / Revenue TTM)
Gross Margin QoQ = 24.14% (prev 39.52%)
Tobins Q-Ratio = 3.46 (Enterprise Value 996.6m / Total Assets 288.2m)
Interest Expense / Debt = 0.16% (Interest Expense 33.0k / Debt 20.2m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -207.4m (EBIT -262.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.66 (Total Current Assets 249.5m / Total Current Liabilities 37.5m)
Debt / Equity = 0.09 (Debt 20.2m / totalStockholderEquity, last quarter 230.5m)
 Debt / EBITDA = 0.78 (negative EBITDA) (Net Debt -202.3m / EBITDA -260.1m)
 Debt / FCF = 0.75 (negative FCF - burning cash) (Net Debt -202.3m / FCF TTM -271.5m)
 Total Stockholder Equity = 245.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -83.47% (Net Income -271.6m / Total Assets 288.2m)
RoE = -110.5% (Net Income TTM -271.6m / Total Stockholder Equity 245.7m)
 RoCE = -104.7% (out of range, set to none) (EBIT -262.5m / Capital Employed (Total Assets 288.2m - Current Liab 37.5m))
 RoIC = -82.83% (negative operating profit) (NOPAT -207.4m / Invested Capital 250.4m)
 WACC = 8.80% (E(1.20b)/V(1.22b) * Re(8.95%) + D(20.2m)/V(1.22b) * Rd(0.16%) * (1-Tc(0.21)))
Discount Rate = 8.95% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 37.27%
 [DCF] Fair Price = unknown (Cash Flow -271.5m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -2.77 | # QB: -1
Revenue Correlation: -48.09 | Revenue CAGR: -24.78% | SUE: 0.06 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.95 | Chg30d=-1.27% | Revisions=-58% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.80 | Chg30d=-1.26% | Revisions=-18% | Analysts=10
EPS current Year (2026-12-31): EPS=-3.51 | Chg30d=-0.92% | Revisions=-42% | GrowthEPS=-10.8% | GrowthRev=-94.6%
EPS next Year (2027-12-31): EPS=-2.82 | Chg30d=-0.01% | Revisions=-18% | GrowthEPS=+19.6% | GrowthRev=+2888.0%
[Analyst] Revisions Ratio: -43% (up=9, down=25)